{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:00:07Z","timestamp":1774598407008,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R25"],"award-info":[{"award-number":["R25"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R25 MH1112473"],"award-info":[{"award-number":["R25 MH1112473"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005386","name":"American Psychiatric Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005386","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K12"],"award-info":[{"award-number":["K12"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K12 DA041449"],"award-info":[{"award-number":["K12 DA041449"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.dadr.2024.100303","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T17:17:24Z","timestamp":1732295844000},"page":"100303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cannabidiol prescribing in the United States: An analysis of real-world data"],"prefix":"10.1016","volume":"13","author":[{"given":"Binx Yezhe","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Lessard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallawi","family":"Jyotsana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Steinle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob T.","family":"Borodovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1bio A.","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin Y.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dadr.2024.100303_bib1","first-page":"485","article-title":"Emerging use of epidiolex (Cannabidiol) in epilepsy","volume":"25","author":"Abu-Sawwa","year":"2020","journal-title":"J. Pedia Pharm. Ther."},{"key":"10.1016\/j.dadr.2024.100303_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108325","article-title":"Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"124","author":"Anderson","year":"2021","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.dadr.2024.100303_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2147\/CLEP.S333534","article-title":"Measuring medication adherence in a population-based asthma administrative pharmacy database: a systematic review and meta-analysis","volume":"13","author":"Asamoah-Boaheng","year":"2021","journal-title":"Clin. Epidemiol."},{"issue":"7","key":"10.1016\/j.dadr.2024.100303_bib4","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1007\/s11606-020-06504-8","article-title":"Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review","volume":"36","author":"Balachandran","year":"2021","journal-title":"J. Gen. Intern Med"},{"issue":"5","key":"10.1016\/j.dadr.2024.100303_bib5","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14130","article-title":"Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial","volume":"83","author":"Berger","year":"2022","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.dadr.2024.100303_bib6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s40263-020-00773-x","article-title":"Cannabinoids in the treatment of insomnia disorder: a systematic review and meta-analysis","volume":"34","author":"Bhagavan","year":"2020","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.dadr.2024.100303_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00213-020-05712-8","article-title":"Cannabidiol: pharmacology and therapeutic targets","volume":"238","author":"Britch","year":"2021","journal-title":"Psychopharmacol. (Berl. )"},{"issue":"2","key":"10.1016\/j.dadr.2024.100303_bib8","article-title":"Psychiatric comorbidities in children with conduct disorder: a descriptive analysis of real-world data","volume":"37","author":"Brown","year":"2024","journal-title":"Gen. Psychiatr."},{"key":"10.1016\/j.dadr.2024.100303_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106635","article-title":"Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: systematic review and meta-analysis","volume":"102","author":"de Carvalho Reis","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.dadr.2024.100303_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex(R)) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"6","key":"10.1016\/j.dadr.2024.100303_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/17425255.2020.1754793","article-title":"Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials","volume":"16","author":"Dos Santos","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.dadr.2024.100303_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9126","article-title":"Adverse events of cannabidiol use in patients with epilepsy: a systematic review and meta-analysis","volume":"6","author":"Fazlollahi","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.dadr.2024.100303_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.seizure.2020.09.010","article-title":"Interaction of cannabidiol with other antiseizure medications: a narrative review","volume":"86","author":"Gilmartin","year":"2021","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.dadr.2024.100303_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/0883073816669450","article-title":"Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases","volume":"32","author":"Gofshteyn","year":"2017","journal-title":"J. Child Neurol."},{"issue":"1","key":"10.1016\/j.dadr.2024.100303_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41398-022-02104-8","article-title":"Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study","volume":"12","author":"Hacohen","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.dadr.2024.100303_bib16","unstructured":"JazzPharmaceuticals, 2023. Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance."},{"key":"10.1016\/j.dadr.2024.100303_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.yebeh.2019.05.037","article-title":"Marijuana use among patients with epilepsy at a tertiary care center","volume":"97","author":"Kerr","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.dadr.2024.100303_bib18","article-title":"Use of non-medical cannabis in epilepsy: a scoping review","volume":"14","author":"Li","year":"2023","journal-title":"Front Neurol."},{"key":"10.1016\/j.dadr.2024.100303_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108514","article-title":"Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: implications for patients and practitioners","volume":"127","author":"Miller","year":"2022","journal-title":"Epilepsy Behav."},{"issue":"2","key":"10.1016\/j.dadr.2024.100303_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"4","key":"10.1016\/j.dadr.2024.100303_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/PG9.0000000000000253","article-title":"Persistent diarrhea and eosinophilic esophagitis resulting from chronic cannabidiol usage for refractory epilepsy","volume":"3","author":"Patel","year":"2022","journal-title":"JPGN Rep."},{"issue":"22","key":"10.1016\/j.dadr.2024.100303_bib22","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1001\/jama.2019.17361","article-title":"Cannabidiol products are everywhere, but should people be using them?","volume":"322","author":"Rubin","year":"2019","journal-title":"JAMA"},{"issue":"58","key":"10.1016\/j.dadr.2024.100303_bib23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jncimonographs\/lgab011","article-title":"The management of cancer symptoms and treatment-induced side effects with cannabis or cannabinoids","volume":"2021","author":"Sexton","year":"2021","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"2","key":"10.1016\/j.dadr.2024.100303_bib24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/03602532.2024.2346767","article-title":"Effects of cannabidiol and Delta(9)-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review","volume":"56","author":"Smith","year":"2024","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.dadr.2024.100303_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114238","article-title":"Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis","volume":"359","author":"Talwar","year":"2023","journal-title":"Exp. Neurol."},{"issue":"7","key":"10.1016\/j.dadr.2024.100303_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11070615","article-title":"The impact of marijuana on antidepressant treatment in adolescents: clinical and pharmacologic considerations","volume":"11","author":"Vaughn","year":"2021","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.dadr.2024.100303_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/epi4.12956","article-title":"Consensus panel recommendations for the optimization of EPIDIOLEX(R) treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.","author":"Wechsler","year":"2024","journal-title":"Epilepsia Open"},{"issue":"12","key":"10.1016\/j.dadr.2024.100303_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.47373","article-title":"Past-year use prevalence of cannabidiol, cannabigerol, cannabinol, and Delta8-tetrahydrocannabinol among US adults","volume":"6","author":"Wilson-Poe","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.dadr.2024.100303_bib29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/can.2019.0052","article-title":"Use of cannabidiol for the treatment of anxiety: a short synthesis of pre-clinical and clinical evidence","volume":"5","author":"Wright","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.dadr.2024.100303_bib30","series-title":"Epilepsia Open","article-title":"Antiseizure medication prescribing in people with dravet syndrome: An analysis of real-time administrative data","author":"Xu","year":"2024"},{"issue":"2","key":"10.1016\/j.dadr.2024.100303_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/jamaneurol.2018.3550","article-title":"The US food and drug administration's authorization of the first cannabis-derived pharmaceutical: are we out of the haze?","volume":"76","author":"Yang","year":"2019","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.dadr.2024.100303_bib32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/08830738211069790","article-title":"Complementary and alternative medicine (CAM) use in children with epilepsy","volume":"37","author":"Zhu","year":"2022","journal-title":"J. Child Neurol."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724624000878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724624000878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T08:30:14Z","timestamp":1736670614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724624000878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":32,"alternative-id":["S2772724624000878"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100303","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol prescribing in the United States: An analysis of real-world data","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100303"}}